ZIA BC 011415 (ZIA) | |||
---|---|---|---|
Title | Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Kochenderfer, James | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $19,101 | Project Dates | null - null |
Fiscal Year | 2018 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Bone Marrow Transplantation (100.0%) Cancer (100.0%) Gene Therapy (100.0%) Gene Therapy Clinical Trials (20.0%) |
Leukemia (67.0%) Non Hodgkins Lymphoma (33.0%) |
||
Research Type | |||
Systemic Therapies - Discovery and Development Systemic Therapies - Clinical Applications |
|||
Abstract | |||
This trial is one of few CAR trials exclusively focused on applying anti-CD19 CAR T cells to the allogeneic transplantation setting. This trial is significant because unlike most trials of anti-CD19 chimeric antigen receptors, it does not include chemotherapy, so it gives a pure assessment of the activity of the anti-CD19 CAR T cells. We continue recruit more patients for this trial. We are obtaining important information on toxicity and predictors of successful therapy with each patient. A paper covering this trial (Brudno et al.) was published in the Journal of Clinical Oncology in 2016. The project is now focused on testing less-differentiated T cells called stem memory T cells (Ttscm) transduced with an anti-CD19 CAR. In this effort, we are currently collaborating with another ETIB Investigator, Luca Gattinoni, in developing a process for administering allogeneic anti-CD19 CAR stem memory T cells. The cell production process for Tscm cells has been put in place, and we have treated the first 2 patients with anti-CD19 CAR Tscm cells on this clinical trial. One patient obtained a response of stable disease after her lymphoma was treated with these anti-CD19 CAR Tscm cells. The second patient, with acute lymphoid leukemia, obtained a complete remission. We will continue to treat more patients and to carry out extensive correlative studies of patient samples from this clinical trial |